Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CEO Chad M. Robins sold 99,107 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $8.44, for a total transaction of $836,463.08. Following the completion of the sale, the chief executive officer now directly owns 2,576,701 shares of the company's stock, valued at approximately $21,747,356.44. This trade represents a 3.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Adaptive Biotechnologies Stock Performance
Shares of ADPT stock opened at $8.27 on Friday. The firm's 50 day moving average price is $7.20 and its 200-day moving average price is $5.77. Adaptive Biotechnologies Co. has a one year low of $2.28 and a one year high of $8.95. The firm has a market cap of $1.22 billion, a P/E ratio of -7.59 and a beta of 1.50.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.04. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. During the same period last year, the company posted ($0.30) EPS. As a group, research analysts predict that Adaptive Biotechnologies Co. will post -0.94 EPS for the current fiscal year.
Analyst Ratings Changes
Several analysts have recently weighed in on the stock. Scotiabank increased their price target on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the company a "sector outperform" rating in a research note on Thursday, February 13th. The Goldman Sachs Group increased their price target on shares of Adaptive Biotechnologies from $5.50 to $7.50 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. Finally, Piper Sandler restated an "overweight" rating and issued a $11.00 price objective (up from $7.00) on shares of Adaptive Biotechnologies in a report on Thursday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Adaptive Biotechnologies has a consensus rating of "Moderate Buy" and a consensus price target of $9.10.
Check Out Our Latest Analysis on ADPT
Institutional Investors Weigh In On Adaptive Biotechnologies
A number of hedge funds have recently added to or reduced their stakes in the business. Impact Partnership Wealth LLC lifted its holdings in Adaptive Biotechnologies by 8.8% during the 4th quarter. Impact Partnership Wealth LLC now owns 19,078 shares of the company's stock worth $114,000 after buying an additional 1,539 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Adaptive Biotechnologies by 2.7% during the 4th quarter. Russell Investments Group Ltd. now owns 80,994 shares of the company's stock worth $486,000 after buying an additional 2,163 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Adaptive Biotechnologies by 4.1% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,916 shares of the company's stock worth $395,000 after buying an additional 2,625 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Adaptive Biotechnologies by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,292 shares of the company's stock worth $188,000 after buying an additional 2,928 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in Adaptive Biotechnologies by 5.6% during the 4th quarter. MetLife Investment Management LLC now owns 68,976 shares of the company's stock worth $414,000 after buying an additional 3,650 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
